Zydus Cadila's 3-dose Covid Vaccine ZyCov-D Gets Govt Panel Nod

The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6% in a late-stage trial of more than 28,000 volunteers nationwide.

from Top India News- News18.com https://ift.tt/3mmPchc